0001179110-14-011788.txt : 20140716
0001179110-14-011788.hdr.sgml : 20140716
20140716182518
ACCESSION NUMBER: 0001179110-14-011788
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140714
FILED AS OF DATE: 20140716
DATE AS OF CHANGE: 20140716
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quisel John D
CENTRAL INDEX KEY: 0001586788
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 14978922
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2014-07-14
0
0001280600
ACCELERON PHARMA INC
XLRN
0001586788
Quisel John D
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP Gen. Counsel & Secretary
Common Stock
2014-07-14
4
M
0
2000
0.92
A
2000
D
Common Stock
2014-07-14
4
S
0
1100
28.70
D
900
D
Common Stock
2014-07-14
4
S
0
900
29.71
D
0
D
Common Stock
2014-07-14
4
M
0
3000
5.28
A
3000
D
Common Stock
2014-07-14
4
S
0
3000
30.12
D
0
D
Option to Purchase Common Stock
0.92
2014-07-14
4
M
0
2000
0
D
2016-11-15
Common Stock
21500
19500
D
Option to Purchase Common Stock
5.28
2014-07-14
4
M
0
3000
0
D
2021-12-16
Common Stock
16010
13010
D
The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.29 to $29.07, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.40 to $30.31, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.01 to $30.30, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter.
The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.
/s/ John D Quisel
2014-07-16